A Phase I Study of Concurrent Chemotherapy and Radiation Therapy for Patients with Inoperable Malignant Pleural Mesothelioma

Full Title

A Phase I Study of Concurrent Pemetrexed/Cisplatin with Pleural Intensity Modulated Radiation Therapy for Patients with Unresectable Malignant Pleural Mesothelioma

Purpose

Intensity-modulated radiation therapy (IMRT) is a highly precise radiation treatment that can help control pleural mesothelioma growth when given after chemotherapy is completed. The radiation is directed to the lining of the lungs (pleura) without damaging the lungs themselves.

In this study, researchers want to see if giving IMRT during the same period that a patient is receiving chemotherapy (the drugs cisplatin and pemetrexed) is safe for treating inoperable pleural mesothelioma. They'll be evaluating different doses of these drugs to determine the highest dosage that can be given safely. If this treatment is shown to be safe, additional studies will be done to see if concurrent chemotherapy and IMRT can help control tumor growth longer than the standard approach of IMRT after chemotherapy.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable malignant pleural mesothelioma.
  • Patients may have had up to one prior regimen of chemotherapy.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Marjorie Zauderer at 646-888-4656.

Protocol

15-304

Phase

I

Investigator

Co-Investigators

Diseases